Accordingly, most preclinical and clinical MM studies to date have focused on the key immunotherapy antigens BCMA, CD38 and SLAMF7, with the latter two being the target of three already FDA-approved mAbs. This evidence concerns the gene CD38 and Miyoshi myopathy.